Betahistine-LF tablets 24mg №10×3

Name:
Betahistine-LF tab 24mg cont cell pack No. 10×3
Description:
Tablets of white or almost white color, flat-cylindrical shape, with a bevel and a risk (for dosages of 16 mg and 24 mg). Marbling may be observed. The main active ingredient Betahistine Release form Tablets Dosage 24 mg Pharmacotherapeutic group Preparations for the elimination of dizziness Pharmacodynamics The mechanism of action of betahistine is partially known. In vitro, betahistine facilitates histaminergic transmission due to its partial H1 agonist and H3 antagonist effects. In animals, after intravenous administration, betahistine reduces the electrical activity of polysynaptic neurons of the vestibular nuclei. Betahistine does not cause sedation. Absorption and distribution When administered orally, betahistine is rapidly and almost completely absorbed. Eating significantly slows down the absorption of betahistine without changing the level of absorption. Metabolism and excretion Betahistine is excreted in the urine as 2-pyridylacetic acid. The half-life is approximately 3.5 hours. Almost completely eliminated within 24 hours. Indications for use Symptomatic treatment of recurrent vertigo with or without cochlear symptoms. Dosage and administration Inside, during meals, the tablets are swallowed without chewing, with a glass of water. The risk on the 16 mg and 24 mg tablets is intended solely to facilitate taking one tablet (by breaking the tablet into two halves), and not to divide the tablet into two doses. The recommended duration of treatment is 2 to 3 months, treatment can be extended depending on the course of the disease, intermittent or continuous courses. Betahistine-LF 24 mg This dosage form is intended for use in patients requiring a daily dose of 48 mg betahistine. In other cases, lower doses should be used. The usual dosage is 1 tablet 2 times a day. Special groups of patients Impaired renal function. There are no data on the use in patients with renal insufficiency. Liver dysfunction. There are no data on the use in patients with hepatic insufficiency. Elderly patients. Extensive post-marketing experience indicates that dose adjustment in elderly patients is not required. However, Betahistine-LF should be used with caution in elderly patients because the available safety data are limited. Children. Betahistine-LF is not recommended for use in children and adolescents under the age of 18 due to insufficient data on efficacy and safety. Use during pregnancy and lactation Pregnancy Studies in animals have not shown any teratogenic effect. Given the absence of any teratogenic effect in animals, no malformative effect is expected in humans. Substances that cause malformations in humans are now considered to have a proven teratogenic effect in animals in well-controlled studies in two animal species. So far, not enough relevant data have been obtained to assess the possible teratogenic or embryotoxic effect of betahistine when used during pregnancy. Therefore, as a precautionary measure, it is not recommended to take betahistine during pregnancy. Lactation Since there are no data on the excretion of betahistine in breast milk, the risk is not known; therefore, breast-feeding is not recommended during the period of betahistine use. Influence on the ability to drive vehicles or potentially dangerous mechanisms There is no data on the effect of the drug on the ability to drive vehicles or other mechanisms. Precautions and application features Patients with bronchial asthma require careful monitoring during therapy with betahistine (risk of bronchospasm). Taking the drug with meals can prevent pain in the stomach. Betahistine is not recommended for the treatment of the following pathological conditions: benign paroxysmal dizziness; dizziness associated with damage to the central nervous system. Interaction with other drugs There are no data on drug interactions. Contraindications Hypersensitivity to betahistine dihydrochloride or any of the excipients of the drug. Active phase of peptic ulcer. Pheochromocytoma. Composition Each tablet contains: active substance: betahistine dihydrochloride – 24 mg; excipients: anhydrous citric acid, mannitol, anhydrous colloidal silicon dioxide, crospovidone, talc, microcrystalline cellulose. OverdoseSymptoms: Symptoms are similar to those caused by histamine. Treatment: Prescribe antihistamines. Side effect The frequency of adverse reactions indicated below was determined using the following note: very often (> 1/10), often (> 1/100 – < 1/10), infrequently (> 1/1.000 – < 1/100), rarely (> 1/10.000 – < 1/1.000), very rare (< 1/10.000), not known (cannot be determined from the available data). Blood and lymphatic system disorders: unknown - thrombocytopenia. Immune system disorders: rarely - hypersensitivity reactions. Mental disorders: rarely - drowsiness. Nervous system disorders: rarely - headaches, asthenia. From the gastrointestinal tract: often - pain in the stomach, nausea, vomiting, dry mouth, diarrhea. Liver and biliary tract disorders: unknown - increased transaminase levels. Storage conditions In a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Buy Betahistine-LF tablets 24mg No. 10x3 Price for Betahistine-LF tablets 24mg No. 10x3